JP2023544385A5 - - Google Patents
Info
- Publication number
- JP2023544385A5 JP2023544385A5 JP2023520289A JP2023520289A JP2023544385A5 JP 2023544385 A5 JP2023544385 A5 JP 2023544385A5 JP 2023520289 A JP2023520289 A JP 2023520289A JP 2023520289 A JP2023520289 A JP 2023520289A JP 2023544385 A5 JP2023544385 A5 JP 2023544385A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086495P | 2020-10-01 | 2020-10-01 | |
| US63/086,495 | 2020-10-01 | ||
| PCT/US2021/052580 WO2022072447A1 (en) | 2020-10-01 | 2021-09-29 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544385A JP2023544385A (ja) | 2023-10-23 |
| JP2023544385A5 true JP2023544385A5 (https=) | 2024-10-07 |
| JPWO2022072447A5 JPWO2022072447A5 (https=) | 2024-10-07 |
Family
ID=80950831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520289A Pending JP2023544385A (ja) | 2020-10-01 | 2021-09-29 | Ｓｎｃａ関連神経変性疾患を治療又は予防するためのｓｎｃａ ｉｒｎａ組成物及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240011032A1 (https=) |
| EP (1) | EP4221838A4 (https=) |
| JP (1) | JP2023544385A (https=) |
| KR (1) | KR20230079405A (https=) |
| CN (1) | CN116710107A (https=) |
| AR (1) | AR123679A1 (https=) |
| AU (1) | AU2021353935A1 (https=) |
| CA (1) | CA3193830A1 (https=) |
| IL (1) | IL301712A (https=) |
| MX (1) | MX2023003810A (https=) |
| TW (1) | TW202229551A (https=) |
| WO (1) | WO2022072447A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119630791A (zh) * | 2022-05-13 | 2025-03-14 | 迪克纳制药公司 | 用于抑制snca表达的组合物和方法 |
| US20260103703A1 (en) * | 2022-09-29 | 2026-04-16 | Atalanta Therapeutics, Inc. | siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS |
| WO2024166019A1 (en) * | 2023-02-08 | 2024-08-15 | Biorchestra Co., Ltd. | Sirna targeting alpha-synuclein and uses thereof |
| AU2024335806A1 (en) * | 2023-09-07 | 2026-04-23 | Janssen Pharmaceutica Nv | SNCA siRNA AND USES THEREOF |
| WO2025162214A1 (en) * | 2024-01-30 | 2025-08-07 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of synuclein alpha (snca) gene |
| TW202547527A (zh) * | 2024-02-08 | 2025-12-16 | 日商泰爾茂股份有限公司 | 寡核苷酸 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP2508608A1 (en) * | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| WO2005045034A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) |
| US20080003570A1 (en) * | 2004-12-22 | 2008-01-03 | The General Hospital Corporation | Translation enhancer elements of genes encoding human Tau protein and human alpha-synuclein protein |
| US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| CA3077910A1 (en) * | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| CN108728533B (zh) * | 2017-04-20 | 2022-06-14 | 常青 | 用于髓母细胞瘤分子分型的基因群以及snca基因作为4型髓母细胞瘤的生物标志物的用途 |
| AU2019207859A1 (en) * | 2018-01-12 | 2020-07-02 | Roche Innovation Center Copenhagen A/S | Alpha-synuclein antisense oligonucleotides and uses thereof |
| WO2019217459A1 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| EP3830265A1 (en) * | 2018-08-03 | 2021-06-09 | Genzyme Corporation | Variant rnai against alpha-synuclein |
-
2021
- 2021-09-29 AU AU2021353935A patent/AU2021353935A1/en active Pending
- 2021-09-29 EP EP21876366.2A patent/EP4221838A4/en active Pending
- 2021-09-29 JP JP2023520289A patent/JP2023544385A/ja active Pending
- 2021-09-29 US US18/247,314 patent/US20240011032A1/en active Pending
- 2021-09-29 CN CN202180081220.XA patent/CN116710107A/zh active Pending
- 2021-09-29 KR KR1020237014415A patent/KR20230079405A/ko active Pending
- 2021-09-29 WO PCT/US2021/052580 patent/WO2022072447A1/en not_active Ceased
- 2021-09-29 IL IL301712A patent/IL301712A/en unknown
- 2021-09-29 CA CA3193830A patent/CA3193830A1/en active Pending
- 2021-09-29 MX MX2023003810A patent/MX2023003810A/es unknown
- 2021-09-30 TW TW110136531A patent/TW202229551A/zh unknown
- 2021-10-01 AR ARP210102736A patent/AR123679A1/es unknown